https://orcid.org/0000-0002-3132-5778
Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Alexia Bikou, Foteini Dermiki-Gkana, Michail Penteris, Theodoros K Constantinides & Christos Kontogiorgis. (2024) A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opinion on Pharmacotherapy 0:0, pages 1-9.
Read now
Read now
Carel Le Roux & Alvin Mondoh. (2024) Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?. Expert Opinion on Pharmacotherapy 25:2, pages 131-138.
Read now
Read now
Articles from other publishers (13)
Alberte Laura Oest Müllertz, Rasmus Michael Sandsdal, Simon Birk Kjær Jensen & Signe Sørensen Torekov. (2024) Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obesity Reviews 25:5.
Crossref
Crossref
Alexandre Dréant, Claire Blanchard & David Jacobi. (2024) Adjuvant Glucose-Like Peptide 1 Receptor Agonist Therapy for Suboptimal Weight Loss After Bariatric Surgery: a Systematic Review. Obesity Surgery 34:5, pages 1846-1854.
Crossref
Crossref
Oluwafunke O. Ogunremi, Sana F. Ismail, Ramneek K. Dhami, Jazmin S. Newton, Scott A. Kindle & Valeriy Kozmenko. (2024) A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists. International Journal of Women’s Dermatology 10:2, pages e143.
Crossref
Crossref
Walter Masson, Martín Lobo, Leandro Barbagelata, Augusto Lavalle-Cobo & Juan P. Nogueira. (2024) Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis. Endocrinología, Diabetes y Nutrición 71:3, pages 124-132.
Crossref
Crossref
Walter Masson, Martín Lobo, Leandro Barbagelata, Augusto Lavalle-Cobo & Juan P. Nogueira. (2024) Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis. Endocrinología, Diabetes y Nutrición (English ed.) 71:3, pages 124-132.
Crossref
Crossref
Federica Giofrè, Vincenzo Trapanese, Maria Resilde Natale, Clara Vatalaro, Francesca Cosentino, Melania Melina, Maria Chiara Pelle, Nazareno Carullo, Maria Capria & Franco Arturi. (2024) Semaglutide and kidney function: friends or enemies?. Italian Journal of Medicine 18:1.
Crossref
Crossref
Peter Y.W. Chan, Aleksander P. Mika, J. Ryan Martin & Jacob M. Wilson. (2024) Glucagon-like Peptide-1 Agonists. JBJS Reviews 12:1.
Crossref
Crossref
Dalgisio Lecis, Francesca Romana Prandi, Lucy Barone, Martina Belli, Domenico Sergi, Susanna Longo, Saverio Muscoli, Francesco Romeo, Massimo Federici, Stamatios Lerakis & Francesco Barillà. (2023) Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born?. Biomolecules 13:12, pages 1695.
Crossref
Crossref
Mark A. Moyad. (2023) Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.). Current Urology Reports 24:11, pages 515-525.
Crossref
Crossref
Nimra Klair, Utkarsh Patel, Ayushi Saxena, Dhara Patel, Ismat E Ayesha, Neetha R Monson & Shivana Ramphall. (2023) What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue. Cureus.
Crossref
Crossref
N.A. Sanina, N.O. Hondulenko, S.S. Panina & V.S. Shulha. (2023) A clinical case of asymptomatic pancreatic hyperenzymemia on the background of taking a Glucagon-like peptide-1 analogue (GLP-1). Medicni perspektivi 28:3, pages 213-217.
Crossref
Crossref
Magda Wojtara, Ashmita Mazumder, Yusra Syeda & Nikodem Mozgała. (2023) Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management. Advances in Medicine 2023, pages 1-7.
Crossref
Crossref
Frederik Flindt Kreiner, Bernt Johan von Scholten, Peter Kurtzhals & Stephen Charles Langford Gough. (2023) Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials. Aging Cell 22:5.
Crossref
Crossref